Digital Repository

Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka

Show simple item record

dc.contributor.author Schousboe, M.L. en_US
dc.contributor.author Rajakaruna, R.S. en_US
dc.contributor.author Salanti, A. en_US
dc.contributor.author Hapuarachchi, H.A.C. en_US
dc.contributor.author Galappaththi, G.N. en_US
dc.contributor.author Bygbjerg, I.C. en_US
dc.contributor.author Amerasinghe, P.H. en_US
dc.contributor.author Konradsen, F. en_US
dc.contributor.author Alifrangis, M. en_US
dc.date.accessioned 2014-10-29T09:25:18Z
dc.date.available 2014-10-29T09:25:18Z
dc.date.issued 2007 en_US
dc.identifier.citation Malaria Journal. 2007; 9(6): pp.28 en_US
dc.identifier.issn 1475-2875 (Electronic) en_US
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/1805
dc.description Indexed in MEDLINE
dc.description.abstract BACKGROUND: Single nucleotide polymorphisms (SNPs) in the Plasmodium vivax dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase(Pvdhps) genes cause parasite resistance to the antifolate drug combination, sulphadoxine/pyrimethamine (SP). Monitoring these SNPs provide insights into the level of drug pressure caused by SP use and presumably other antifolate drugs. In Sri Lanka, chloroquine (CQ) with primaquine (PQ) and SP with PQ is used as first and second line treatment, respectively, against uncomplicated Plasmodium falciparum and/or P. vivax infections. CQ/PQ is still efficacious against P. vivax infections, thus SP is rarely used and it is assumed that the prevalence of SNPs related to P. vivax SP resistance is low. However, this has not been assessed in Sri Lanka as in most other parts of Asia. This study describes the prevalence and distribution of SNPs related to P. vivax SP resistance across Sri Lanka. SUBJECTS AND METHODS: P. vivax-positive samples were collected from subjects presenting at government health facilities across nine of the major malaria endemic districts on the island. The samples were analysed for SNPs/haplotypes at codon 57, 58, 61 and 117 of the Pvdhfr gene and 383, 553 and 585 of the Pvdhps gene by applying PCR followed by a hybridization step using sequence specific oligonucleotide probes (SSOPs) in an ELISA format. RESULTS: In the study period, the government of Sri Lanka recorded 2,149 P. vivax cases from the nine districts out of which, 454 (21.1%) blood samples were obtained. Pvdhfr haplotypes could be constructed for 373 of these. The FSTS wild-haplotype was represented in 257 samples (68.9%), the double mutant LRTS haplotype was the most frequently observed mutant (24.4%) while the triple mutation (LRTN) was only identified once. Except for two samples of the single mutated Pvdhps GAV haplotype, the remaining samples were wildtype. Geographical differences were apparent, notably a significantly higher frequency of mutant Pvdhfr haplotypes was observed in the Northern districts. CONCLUSION: Since SP is rarely used in Sri Lanka, the high frequency and diversity of Pvdhfr mutations was unexpected indicating the emergence of drug resistant parasites despite a low level of SP drug pressure.
dc.publisher BioMed Central en_US
dc.subject Malaria, Vivax
dc.subject Plasmodium vivax
dc.title Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivax dihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka en_US
dc.type Article en_US
dc.identifier.department Parasitology en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account